“The adverse event during phase I clinical trials during August 2020 was reported to the CDSCO-DCGI within 24 hours of its occurrence and confirmation. The adverse event was investigated thoroughly and determined as not vaccine related,” the company said in a statement.
Unlike Bharat Biotech, AstraZeneca and Johnson & Johnson had temporarily halted their phase 3 clinical trial immediately after an adverse event was observed in a patient each after they received their respective vaccines.
-
The adverse event occurred in a 35-year old participant with no co-morbidities, who was part of Phase 1 trials at a site in western India.
-
The participant was hospitalised with viral pneumonitis, a couple of days after being administered the vaccine. He was discharged after a week’s stay in the hospital.
“All treatment costs for the subject was fully paid for by the sponsor, and the subject is safe,” Bharat Biotech said.
CONCLUSION
-
Bharat Biotech is conducting three-stage clinical trials of Covaxin, a wholly-inactivated novel coronavirus vaccine, in collaboration with apex bio-research agency the Indian Council of Medical Research.
-
Bharat Biotech said it submitted all documentation within timelines, and as mandated by the ethics committees and CDSCO, including a complete causality report.
- The company says it got an approval for the next two phases of clinical trials only after a detailed investigation of the incident was completed.
-
Bharat Biotech earlier this week started its third and final stage of the clinical trial at Nizam’s Institute of Medical Sciences in Hyderabad.
-
The company plans to enroll up to 26,000 participants in the massive phase 3 trial, the largest efficacy trial ever in India, expected to cost the company about ₹150 crore.